Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event
Live webcast followed by an interactive Q&A session on Thursday, May 22ndat 4:00 PM ET
Access the eventhere
THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the Virtual Investor Closing Bell Series on Thursday, May 22, 2025 at 4:00 PM ET.
As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, will provide a corporate overview and discuss the Company's first-in-class platform system technology, a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. In addition, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
The live video webcast will be available on the Events page under the Investors section of the Company's website ( autonomix.com ). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ('Jupiter' or the 'Company'), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia™, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter's strategy to generate near-term revenue while maintaining momentum in its clinical pipeline. Nugevia's debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter's proprietary JOTROL™ micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space. 'The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,' said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. 'By building on the same proprietary technology platform that underpins our prescription drug development, we're delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.' A New Standard in Evidence-Based Supplementation Nugevia's first three formulations—targeting mitochondrial support, mental clarity, and "beauty from within"—will be sold via a direct-to-consumer (DTC) model starting in Q3 2025. Each product integrates JOTROL™, Jupiter's enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL™ is also the foundation of Jupiter's ongoing therapeutic programs in Parkinson's and Alzheimer's disease. Unlike typical single-ingredient supplements, Nugevia features precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. 'We cracked the code on resveratrol's widely published issue with bioavailability, and now we're unlocking its potential beyond the clinic,' added Rosén. 'Consumers are seeking longevity solutions that are both credible and effective. Nugevia meets that demand.' Strategic Synergy with Core Pipeline The Nugevia launch adds a new dimension to Jupiter's value proposition as a dual-path company—advancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming longevity market, projected to reach $8 trillion by 2030. The Company expects this initiative to provide a self-reinforcing commercial engine, with revenues from Nugevia supporting ongoing clinical trials and expanding its shareholder-aligned business model. 'Nugevia represents more than a product launch—it's a strategic engine for growth,' said Rosén. 'By leveraging our core science in a consumer format, we're creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It's smart capital allocation with real scientific impact.' A digital press kit, including high-resolution product imagery and key brand information, is available at . About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website About JOTROL Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson's Disease. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 'approximates,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@
Yahoo
25 minutes ago
- Yahoo
Abcuro Appoints Courtney Cupples as Chief Commercial Officer
Ms. Cupples brings extensive global commercial leadership and rare disease product launch experience NEWTON, Mass., June 09, 2025--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Courtney Cupples as Chief Commercial Officer (CCO). Ms. Cupples brings more than 25 years of global commercial leadership and rare disease product launch experience. "We are excited to welcome Courtney to Abcuro as a key member of the leadership team as we prepare for the potential commercialization of our lead asset, ulviprubart, currently in Phase 3 clinical development for the potential treatment of inclusion body myositis (IBM), a rare and debilitating muscle disease," said Alex Martin, Chief Executive Officer. "Courtney has extensive expertise in global commercial strategy, commercial team leadership, and has worked on several successful orphan drug launches." Ms. Cupples most recently served as Chief Commercial Officer for Priovant Therapeutics, where she led commercial launch preparation for the company's oral small molecule, brepocitinib, currently in development for the potential treatment of severe autoimmune diseases. She began her career at Genzyme Corporation where she served in various commercial roles for over 11 years, driving expansion of the company's enzyme replacement therapy business in Latin America. She then spent nine years at Alexion Pharmaceuticals where she led the launch of Soliris® (eculizumab) in Latin America, served as leader of the $1 billion global franchise for the atypical hemolytic uremic syndrome (aHUS) indication for (Soliris®) and led the global metabolic disease franchise for Strensiq® (asfotase alfa) and Kanuma® (sebelipase alfa). Following Alexion, Ms. Cupples joined Biohaven Pharmaceuticals to lead commercial strategic planning for the company's clinical-stage rare disease portfolio focused primarily on neuromuscular conditions. Ms. Cupples holds a Bachelor of Arts in Sociology & Anthropology from Swarthmore College. "I am thrilled to join Abcuro's team of innovative, experienced and passionate individuals whose collective commitment to turning groundbreaking science into a potentially life-transforming treatment for people with a devastating disease like IBM is truly inspiring," said Ms. Cupples. "I look forward to partnering with this talented team as we move into this exciting next chapter together, including initial data from the MUSCLE study expected in the first half of 2026." About Ulviprubart Ulviprubart (ABC008) is a first-in-class anti-KLRG1 antibody product candidate capable of selectively depleting highly cytotoxic T cells, while sparing naïve, regulatory and central memory T cells. Ulviprubart is designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia (T-LGLL). The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have each granted orphan drug designation to ulviprubart for the treatment of IBM. About Inclusion Body Myositis (IBM) IBM is a rare and debilitating autoimmune disease in which highly cytotoxic T cells chronically attack muscle tissue leading to progressive weakness and limb muscle atrophy. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. There are currently no available disease-modifying treatment options and no cure for IBM. Based on published epidemiology literature, it is estimated that there are more than 50,000 people with IBM across the US and Europe. About Abcuro Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company's lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at View source version on Contacts Matthew DeYoungInvestor Relations and MediaArgot Partnersabcuro@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Trump-Musk meltdown: key moments in the billionaires' spectacular split
Breaking up is hard to do, and even harder if you are a billionaire who decides to break up with another billionaire on the two social media platforms you own, while the world watches in real time. Here are the key moments as the relationship between the US president, Donald Trump, and his former senior adviser Elon Musk unravelled in spectacular fashion, precipitated by a dispute over a colossal spending bill that could have major consequences for years to come. Tuesday 27 May 2025 Musk criticises Trump's tax and spending bill CBS previewed an interview, scheduled for that weekend, in which Musk said Trump's proposed tax and spending bill 'undermines' the cost-cutting efforts of the 'department of government efficiency' (Doge), which he led. Wednesday 28 May 2025 Musk out of White House Musk announced on social media that he was leaving his role in the Trump administration, a departure that the White House confirmed was in process on the same evening. 'As my scheduled time as a Special Government Employee comes to an end, I would like to thank President @realDonaldTrump for the opportunity to reduce wasteful spending,' the billionaire wrote on X, his social media platform. Friday 30 May Trump's goodbye In the Oval Office, Trump praised Musk for his service, presenting him with a golden key and lauding the 'colossal change' he had brought through Doge – which in four months entered dozens of federal departments, accessed sensitive data and led to the elimination of thousands of jobs, though the ultimate savings were far, far less than Musk had promised. Standing alongside Trump in the Oval Office, Musk, who faced a 130-day limit in his tenure as a special government employee that had ended two days prior, vowed that his departure was 'not the end' of Doge, and that it would 'only strengthen over time'. Tuesday 3 June, 1.31pm ET Musk: 'disgusting abomination' Musk seemed to release a pent-up frustration on X. He said: 'I'm sorry, but I just can't stand it anymore', then derided the administration's One Big Beautiful Bill Act, calling it a 'massive, outrageous, pork-filled Congressional spending bill' that was 'a disgusting abomination'. Wednesday 4 June, 2.07am Musk: bill defeats Doge efforts Musk doubled down in the early hours, claiming the bill 'more than defeats all the cost savings achieved by the Doge team at great personal cost and risk'. Thursday 5 June, 12.01pm ET Trump launches attack at the White House While hosting the freshly appointed German chancellor, Friedrich Merz, Trump skimmed over the diplomatic niceties and instead used the opportunity to engage in a freewheeling discussion about Musk that started positively but got progressively less pleasant. He began by needling Musk for appearing in the Oval Office with a black eye. 'You saw a man who was very happy when he stood behind the Oval desk. And even with the black eye. I said: 'Do you want a little makeup? We'll get you a little makeup.' But he said: 'No, I don't think so.'' (Musk claimed last week that he got the black eye when his five-year-old son, X Æ A-12, punched him in the face.) Trump then said he had 'had' a great relationship with the Tesla boss, but 'I don't know if we will any more', adding: 'I'm very disappointed in Elon. I've helped Elon a lot.' He then accused Musk of being upset that the bill would take away subsidies for electric vehicles. It got worse. 'If you saw the statements he made about me, which I'm sure you can get very easily, it's very fresh on tape, he said the most beautiful things about me, and he hasn't said bad about me personally,' Trump said, but then added, presciently: 'But I'm sure that'll be next.' He went on to accuse Musk of missing the glamour of being in the Oval Office, saying that sometimes people left his administration and became 'hostile' because of 'Trump derangement syndrome'. 'They leave and they wake up in the morning, and the glamour is gone. The whole world is different, and they become hostile, I don't know what it is,' the president said. Merz's face during all of this was a picture. 12.46pm Musk: 'Such ingratitude' Musk, who somehow despite running multiple companies never seems to be offline, was watching the Oval Office meeting and responding in real time. Trump's claim that Musk had known what was in the bill was false, Musk said. He wrote that it 'was passed in the dead of night so fast that almost no one in Congress could even read it'. But what appeared to really get under his skin was Trump saying on Thursday he would have won the presidential election without Musk's help or money. Replying to an X user, Musk said: 'Without me, Trump would have lost the election, Dems would control the House and the Republicans would be 51-49 in the Senate. Such ingratitude.' 1.57pm Time for a new Musk political party? Less than two hours after the White House event, Musk posted a poll on X, asking: 'Is it time to create a new political party in America that actually represents the 80% in the middle?' At the time of writing, 80% of X users who responded had said 'Yes'. 2.16pm Musk says he will be around longer than Trump He then gave us all something to chew on: 'Oh and some food for thought as they ponder this question: Trump has 3.5 years left as President, but I will be around for 40+ years …' Elon Musk is 53 years old. 2.20pm People start offering relationship advice … Ashley St Clair, a rightwing influencer thought to have had a baby called Romulus with Musk, popped up to offer the president some counselling. 2.37pm Trump: 'He just went CRAZY!' Trump was not having any of this: what billionaire narcissist would? He took to the social media platform he owns to claim that he had asked Musk to leave his work with the 'Doge' office because he was, Trump said, 'wearing thin'. 'I asked him to leave, I took away his EV Mandate that forced everyone to buy electric Cars that nobody else wanted … and he just went CRAZY!' Trump wrote, then brazenly suggested he would 'terminate Elon's governmental subsidies and contracts'. Musk immediately responded: 'Such an obvious lie. So sad.' 3.10pm Musk: time to drop the really big Epstein bomb Then he upped the ante. 'Time to drop the really big bomb: Donald Trump is in the Epstein files,' he tweeted, referring to the convicted sex offender Jeffrey Epstein. 'That is the real reason they have not been made public,' Musk wrote, adding in a separate post: 'Mark this post for the future. The truth will come out.' Musk, of course, has himself been pictured with the Epstein associate Ghislaine Maxwell, who was found guilty of sex-trafficking in 2021. (Neither featuring in the files nor being photographed with Maxwell indicates wrongdoing.) 3.33pm Kanye West enters the chat Ye, an erstwhile ally of both men – who has been dropped by sponsors and fans over his antisemitic outbursts – posts: 'Broooos please noooooo,' adding: 'We love you both so much.' 3.45pm House speaker Mike Johnson weighs in Musk had earlier been reposting the House speaker, Mike Johnson, criticising the Joe Biden administration in 2023 for 'an endless cycle of out-of-control deficit spending'. 'Where is the Mike Johnson of 2023!?' Musk asked. Johnson took the bait. 'The Mike Johnson of 2023 is the SAME Mike Johnson who has always been a lifelong fiscal hawk,' he said in a lengthy post. X users were unimpressed and the post wound up with a community note disputing its accuracy. 4.06pm Trump: Musk should have done this months ago Gnomically, the US president wrote: 'I don't mind Elon turning against me, but he should have done so months ago.' 4.09pm Musk: I'm taking my space toys away Musk then threatened to withhold the spacecraft that Nasa has used to travel to and from the International Space Station – which would leave astronauts dependent on Boeing or Russia to get them home. 'SpaceX will begin decommissioning its Dragon spacecraft immediately,' he wrote. As a reminder, Musk is 53. 4.11pm Musk agrees with impeachment call Musk ratcheted things up even further when he amplified a tweet by Gamergater Ian Miles Cheong calling for Trump to be impeached. (If it happened, it would be for a record third time.) 4.26pm Musk says Trump will cause a recession Having backed the US president to the hilt during the election campaign, and joined his administration, Musk then declared: 'The Trump tariffs will cause a recession in the second half of this year.' 4.43pm Musk doubles down on his Epstein line With an 'eyebrow raised' emoji, Musk posted a well-known NBC video of Trump with Epstein at a party in 1992, dancing, joking and making comments about women. 6.48pm 'An unfortunate episode' The White House press secretary, Karoline Leavitt, described the feud as 'an unfortunate episode from Elon'. 9.48pm Musk posts a ketamine meme Musk posted a meme referring to the persistent online suggestions that he uses ketamine and to his associating Trump with Epstein. In 2024, Musk said he used the drug on prescription for medical reasons. The morning after … The opening moves to back down and reconcile seemed to begin … … but then shortly before 7am a reporter asked Trump about the supposed phone call he was going to have with Musk later in the day. 'You mean the man who has lost his mind?' Trump asked. Here we go again …
